Scott Gottlieb Quotes
The higher cost of getting a generic drug approved by regulators means that many old medicines don't face competitors. It's only after substantial price hikes that these drugs offer enough revenue to offset the rising generic entry costs, and start to entice competition.
Gottlieb, Scott. "The FDA's Generic-Drug Monopoly." The Wall Street Journal, 19 Aug. 2016.
The major killer diseases such as malaria and sleeping sickness are not contracted by Americans, and America is the only large country in the world where the Governments allow the drug companies to charge such high prices and make such huge profits. So any drug that Americans might pay for is a better potential profit generator than one that would be critical to the lives of millions where the governments to preserve lives would force the prices down or allow other companies to also make the drug. See {628648} for other factors affecting drug company priorities.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.